Development of a T cell-redirecting bispecific antibody targeting B-cell maturation antigen for the suppression of multiple myeloma cell growth

Abstract Background Multiple myeloma (MM) is the second most common hematological malignancy. It has emerged as one of the next possible hematological diseases amenable to immunotherapy. B-cell maturation antigen (BCMA), a member of the tumor necrosis factor receptor superfamily, is highly expressed...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Antibody Therapeutics 2022-04, Vol.5 (2), p.138-149
Hauptverfasser:	Huo, Jianxin, Huang, Yuhan, Zheng, Ziying, Tay, Xin Ni, Mahfut, Farouq Bin, Zhang, Wei, Lam, Kong-Peng, Yang, Yuansheng, Xu, Shengli
Format:	Artikel
Sprache:	eng
Schlagworte:	Antigens Biological products Drug approval Growth Health aspects Immunotherapy Multiple myeloma Original research article Scientific equipment and supplies industry T cells Tumor necrosis factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!